Goldman Sachs’s Akcea Therapeutics Inc AKCA Stock Holding History

Goldman Sachs’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-30,000	Closed	-$411K	–	5648
2020 Q2	$411K	Sell	30,000 -30,000	-50%	-$463K	﹤0.01%	4470
2020 Q1	$858K	Buy	60,000 +30,000	+100%	+$492K	﹤0.01%	3860
2019 Q4	$508K	Buy	+30,000	New	+$558K	﹤0.01%	4497

Goldman Sachs's AKCA Position: Q4 2020 in Review

Goldman Sachs sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 73,522 shares — an estimated $1.33M sold.

Goldman Sachs first reported a position in AKCA in Q4 2017 and held it in 12 quarters. The position peaked at $1.64M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

Goldman Sachs reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
Goldman Sachs sold 73,522 Akcea Therapeutics Inc shares in Q4 2020, an estimated $1.33M.
Goldman Sachs first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 12 quarters.
Goldman Sachs's Akcea Therapeutics Inc position peaked at $1.64M in Q3 2018.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.